29207-02-1

Basic information

• Product Name: methyl 2-(3,4-dimethoxyphenyl)propanoate
• Synonyms: methyl 2-(3,4-dimethoxyphenyl)propanoate
• CAS NO: 29207-02-1
• Molecular Weight: 224.257
• Mol File: 29207-02-1.mol

Chemical Properties

• CAS DataBase Reference: methyl 2-(3,4-dimethoxyphenyl)propanoate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 2-(3,4-dimethoxyphenyl)propanoate(29207-02-1)
• EPA Substance Registry System: methyl 2-(3,4-dimethoxyphenyl)propanoate(29207-02-1)

Safety Data

• Hazardous Substances Data: 29207-02-1(Hazardous Substances Data)

Upstream product

• 93-40-3 (3,4-Dimethoxyphenyl)acetic acid 
• 15964-79-1 methyl (3,4-dimethoxyphenyl)acetate 
• 74-88-4 methyl iodide 

Downstream Products

• 97611-75-1 2-(3,4-Dimethoxy-phenyl)-2-methyl-pent-4-enoic acid methyl ester 
• 40181-01-9 2-(3,4-dimethoxyphenyl)-1-propanol 
• 1386350-40-8 (R)-2-(3,4-dimethoxyphenyl)-1-(5-methoxy-2,2-dimethyl-2H-chromen-6-yl)propan-1-one 
• 1386351-18-3 (R)-2-(3,4-dimethoxyphenyl)propionaldehyde 
• 1386351-20-7 C₁₁H₁₆O₃ 
• 390815-40-4 (R)-2-(3,4-dimethoxyphenyl)propanoic acid 
• 1386350-39-5 (S)-2-(3,4-dimethoxyphenyl)-1-(5-methoxy-2,2-dimethyl-2H-chromen-6-yl)propan-1-one 
• 1192280-95-7 (S)-2-(3,4-dimethoxyphenyl)propionaldehyde 
• 1386351-16-1 (S)-2-(3,4-dimethoxyphenyl)propanoic acid 
• 1386351-11-6 (R)-2-(3,4-dimethoxyphenyl)-N-((R)-2-hydroxy-1-phenylethyl)propanamide 
• 1386351-09-2 (S)-2-(3,4-dimethoxyphenyl)-N-((R)-2-hydroxy-1-phenylethyl)propanamide 
• 138505-14-3 2-(3,4-dimethoxyphenyl)propanoic acid 

Relevant articles and documents

Chemoenzymatic Cascades toward Methylated Tetrahydroprotoberberine and Protoberberine Alkaloids

Tetrahydroprotoberberine and protoberberine alkaloids are a group of biologically active natural products with complex molecular scaffolds. Isolation from plants is challenging and stereoselective synthetic routes, particularly of methylated compounds are

NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT

The present invention relates to a novel compound inhibiting Hsp 90 and to a pharmaceutical composition including same as an active ingredient. Compounds of formula 1 and formula 2 according to the present invention inhibit the accumulation of HIF-1α protein, which is an Hsp90 client protein, by suppressing Hsp90 expression, and effectively inhibit the activity of vascular endothelial growth factor (VEGF). Furthermore, said compounds have low cytotoxicity and can thus be used as an active ingredient for the treatment of diabetic retinopathy and arthritis.

Design, synthesis, and biological evaluation of novel deguelin-based heat shock protein 90 (HSP90) inhibitors targeting proliferation and angiogenesis

Deguelin exhibits potent apoptotic and antiangiogenic activities in a variety of transformed cells and cancer cells. Deguelin also exhibits potent tumor suppressive effects in xenograft tumor models for many human cancers. Our initial studies confirmed that deguelin disrupts ATP binding to HSP90 and consequently induces destabilization of its client proteins such as HIF-1α. Interestingly, a fluorescence probe assay revealed that deguelin and its analogues do not compete with ATP binding to the N-terminus of HSP90, unlike most HSP90 inhibitors. To determine the key parts of deguelin that contribute to its potent HSP90 inhibition, as well as its antiproliferative and antiangiogenic activities, we have established a structure-activity relationship (SAR) of deguelin. In the course of these studies, we identified a series of novel and potent HSP90 inhibitors. In particular, analogues 54 and 69, the B- and C-ring-truncated compounds, exhibited excellent antiproliferative activities with IC50 of 140 and 490 nM in the H1299 cell line, respectively, and antiangiogenic activities in zebrafish embryos in a dose dependent manner (0.25-1.25 μM).

2, 6 BISHETEROARYL-4-AMINOPYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS

4-Aminopyrimidine derivatives of formula (I) FORMULA heteroaryl groups, including pharmaceutically acceptable salts thereof, wherein R1 and R2 are adenosine A2A receptor antagonists useful in the treatment of movement disorders such as Parkinson's disease.

Application of electrogenerated triphenylmethyl anion as a base for alkylation of arylacetic esters and arylacetonitriles and isomerization of allylbenzenes

Phenylacetic esters and phenylacetonitriles were alkylated with alkyl halides, at the position α to an ester or nitrile, either at room temperature (20 deg C) or at -78 deg C, by making use of electrogenerated triphenylmethyl anion (trityl anion).Double-bond isomerization of allylbenzenes was also effectively accomplished by use of this electrogenerated base (EGB).